Compare Enbridge Inc (ENB) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Natera Inc. Common Stock — how do they compare? Enbridge Inc trades at $47.35 (market cap $105.42B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Enbridge Inc is the larger of the two by market cap, and Enbridge Inc pays a 5.9% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 92 Days and Natera Inc. Common Stock for 0 Days on average.
| ENB | NTRA | |
|---|---|---|
Market Cap | $105.42B | $57.03B |
Volume | 3,621,007 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $58.04 | $425.64 |
52-Week Low | $45.23 | $179.42 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $187.30B | $56.18B |
Dividend Yield | 5.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $47.35, up 0.85% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with three consecutive quarterly earnings beats and a 6% dividend yield. Revenue grew to $65.19 billion in 2025 with net income of $7.49 billion, though 2026 projections show margin compression. Recent news highlights ENB's expansion into European renewables and Permian Basin acquisitions as growth drivers.
ENB offers income investors a stable 6% yield with growth potential from its $41 billion project backlog, but faces headwinds from rising interest rates and potential oil price volatility. Analyst consensus is balanced with 48% buy ratings and a $61.63 price target suggesting 30% upside, though technical indicators remain cautious near-term.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
